{
  "docId": "019de076-f978-76c3-9c95-6b6ce7102162",
  "docSlug": "c02a1d1cb7557bc430cc8dc61cd27097",
  "documentTitle": "CG Oncology | IPO Presentation Deck | 45 slides",
  "authorId": "cg-oncology",
  "authorName": "CG Oncology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 26,
  "pageCount": 45,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "PIVOT-006 trial design slide.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/26",
  "deckHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162",
  "deckJsonHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json",
  "deckAnchorHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "Intermediate-Risk NMIBC -> Cretostimogene vs Observation -> RFS Rate",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f893bce-ad8b-4b9c-9c52-df1766ed7d7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Maintenance course for complete responders weekly x 3 at month 3 and month 6, and once every 3 months at month 9 and month 12. Note: Patients undergo urine cytology and cystoscopy every 3 months for first 2 years; mandatory, site-directed biopsy at month 12.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17a434e4-9332-4386-b371-bfdc13181362",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.38,
        "y": 0.45
      },
      "kind": "list",
      "text": "Study Design / Regimen: Arm A = Cretostimogene Following TURBT (Induction weekly x 6, Maintenance weekly x 3), Arm B = Observation Following TURBT",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6945566e-2171-4fed-aae7-7445254424d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.7,
        "y": 0.45
      },
      "kind": "list",
      "text": "Additional Endpoints: RFS at 12-month and 24-month, PFS, Safety",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70a2a8ce-bd6f-480c-9867-3cc433e38d02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Population: Pathologically confirmed Intermediate-Risk NMIBC (Recurrent LG Ta < 12mo, Solitary LG Ta > 3cm, LG Ta multifocal, HG Ta <= 3cm, LG T1), All disease removed by TURBT at baseline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8fa3193-fb3e-494a-adec-a44fa467ed02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "Phase 3 Adjuvant Cretostimogene Following TURBT Versus Observation Following TURBT for Intermediate Risk NMIBC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93a6812a-d271-4afb-a47e-e70bdc0ee51f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "c9110b64-e1ad-47c1-9519-59c8e7c348dc",
      "evidence": "list/bullet: Population: Pathologically confirmed Intermediate-Risk NMIBC (Recurrent LG Ta < 12mo, Solitary LG Ta > 3cm, LG Ta multifocal, HG Ta <= 3cm, LG T1), All disease removed by TURBT at baseline",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed",
      "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').",
      "position": 0,
      "objective": "What are the consequences of not adopting Cretostimogene?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}